Clinical Research Directory

Inclusion Criteria: * Age 18-80 years old; * Resectable pancreatic body and tail ductal adenocarcinoma with both preoperative and intraoperative evaluation(refer to NCCN guideline 2018 of Pancreatic Cancer); * ECOG Performance Status 0-1; * Adenocarcinoma of pancreatic body and tail duct, without distant metastasis and ascites; * The estimated survival time is ≥ 3 months; * Follow-up in time and obey the research requirements; * Be voluntary to this clinical trial and can sign the informed consent; * Normal hematological index (Leukocyte, platelet, liver function, renal function, DIC, electrolyte index, Hb \>10g/dL). Exclusion Criteria: * The patients with distant metastasis according to preoperative tumor staging; * Patients with recurrent pancreatic ductal adenocarcinoma; * The artery or vein is involved and could not be resected or reconstructed(according to preoperative evaluation or intraoperative evaluation after exploration); * Patients with cardiopulmonary disfunction and cannot tolerate operation; * The patients accepted neoadjuvant chemotherapy and radiotherapy before operation; * Patients with other malignancies or hematopathy * Before the operation, the total bilirubin was more than 250 μmol/L without preoperative biliary drainage or after biliary drainage, the total bilirubin was still more than 250 μmol/L; * Pregnancy diagnosed, planned pregnancy and lactating female patients * Refusal to sign consent. * Intraoperative exclusion include:Tumor metastasis; not pancreatic primary disease; unresectable pancreatic body/tail adenocarcinoma * Postoperative exclusion include: not pancreatic ductal adenocarcinoma according to pathological examination. * Withdrawal of informed consent; * Willingness to withdraw from the study.